SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-20-054995
Filing Date
2020-10-15
Accepted
2020-10-15 20:24:55
Documents
1
Period of Report
2020-10-15

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 5824
  Complete submission text file 0001209191-20-054995.txt   7870
Mailing Address 192 LYTTON AVENUE PALO ALTO CA 94301
Business Address 192 LYTTON AVENUE PALO ALTO CA 94301 (650) 688-0818
Vivo Capital Fund IX, L.P. (Reporting) CIK: 0001750117 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-39614 | Film No.: 201242551

Mailing Address 192 LYTTON AVENUE PALO ALTO CA 94301
Business Address 192 LYTTON AVENUE PALO ALTO CA 94301 6506880818
Vivo Capital IX, LLC (Reporting) CIK: 0001750698 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-39614 | Film No.: 201242550

Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Issuer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)